These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 24184809)
1. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. Guzmán-Fulgencio M; García-Álvarez M; Berenguer J; Jiménez-Sousa MÁ; Cosín J; Pineda-Tenor D; Carrero A; Aldámiz T; Alvarez E; López JC; Resino S J Infect; 2014 Feb; 68(2):176-84. PubMed ID: 24184809 [TBL] [Abstract][Full Text] [Related]
2. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M; AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552 [TBL] [Abstract][Full Text] [Related]
3. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402 [TBL] [Abstract][Full Text] [Related]
4. Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients. García-Álvarez M; Berenguer J; Jiménez-Sousa MÁ; Vázquez-Morón S; Carrero A; Gutiérrez-Rivas M; Aldámiz-Echevarría T; López JC; García-Broncano P; Resino S AIDS; 2016 Apr; 30(7):1069-74. PubMed ID: 27032111 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK J Hepatol; 2013 Mar; 58(3):467-72. PubMed ID: 23183524 [TBL] [Abstract][Full Text] [Related]
6. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Milazzo L; Mazzali C; Bestetti G; Longhi E; Foschi A; Viola A; Vago T; Galli M; Parravicini C; Antinori S Curr HIV Res; 2011 Apr; 9(3):186-93. PubMed ID: 21585333 [TBL] [Abstract][Full Text] [Related]
7. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J; PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696 [TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299 [TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598 [TBL] [Abstract][Full Text] [Related]
11. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF; PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843 [TBL] [Abstract][Full Text] [Related]
12. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
13. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891 [TBL] [Abstract][Full Text] [Related]
14. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Mandorfer M; Payer BA; Schwabl P; Steiner S; Ferlitsch A; Aichelburg MC; Stättermayer AF; Ferenci P; Obermayer-Pietsch B; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T Liver Int; 2015 Mar; 35(3):876-85. PubMed ID: 24905495 [TBL] [Abstract][Full Text] [Related]
15. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. ANRS CO13 HEPAVIH Cohort AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388 [TBL] [Abstract][Full Text] [Related]
16. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070 [TBL] [Abstract][Full Text] [Related]
17. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V; J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic hepatitis C viral infection. Gerova DI; Galunska BT; Ivanova II; Kotzev IA; Tchervenkov TG; Balev SP; Svinarov DA Scand J Clin Lab Invest; 2014 Nov; 74(8):665-72. PubMed ID: 25005344 [TBL] [Abstract][Full Text] [Related]
19. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561 [TBL] [Abstract][Full Text] [Related]
20. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA; Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]